Paul DELMAR,Dorothee Foernzler,Friedemann Krause,Stefan Scherer
申请号：
US13801541
公开号：
US20130195857A1
申请日:
2013.03.13
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall and/or progression-free survival of the patient. The present invention further provides methods for assessing the sensitivity or responsiveness of a pancreatic cancer patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, using similar methods.
